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A B S T R A C T
Background: Restrictive mitral annuloplasty (RMA) can reverse left ventricular (LV) remodeling and
reduce plasma B-type natriuretic peptide (BNP), a surrogate biomarker of heart failure. However, the
relationship between reverse LV remodeling and plasma BNP changes after RMA is poorly deﬁned. We
explored the main hemodynamic factors contributing to change in plasma BNP after RMA in patients
with functional mitral regurgitation (MR).
Methods: Twenty-four patients with moderate to severe functional MR secondary to LV systolic
dysfunction [ejection fraction (EF) <40%] underwent 64-row multidetector computed tomography
(MDCT) before and 1.4 months after RMA. LV end-diastolic volume index (EDVI), end-systolic volume
index (ESVI), LVEF, and regional and global end-systolic wall stress (ESS) were calculated from 3-
dimensional MDCT images, with blood samples for plasma BNP measurement collected the same day.
Results: After RMA, LV volumes and global ESS were decreased, while LVEF improved (all p < 0.01). There
were signiﬁcant correlations between changes in LVEDVI and LVESVI (r = 0.90, p < 0.0001), LVESVI and
global ESS (r = 0.54, p = 0.006), and global ESS and LVEF (r = 0.60, p = 0.002). The median value for the
plasma BNP also decreased from 597 pg/ml [interquartile range (IQR), 360–934 pg/ml] to 207 pg/ml
(IQR, 124–271 pg/ml), in association with changes in LVEDVI (r = 0.47, p = 0.019), LVESVI (r = 0.56,
p = 0.004), LVEF (r = 0.60, p = 0.002), and global ESS (r = 0.74, p < 0.0001). Multivariate regression
analysis showed that global ESS change was the strongest contributor to change in natural-log-
transformed plasma BNP (standardized partial regression coefﬁcient = 0.59, p = 0.004), indicating a
strong association between decrease in LV afterload and reduction in plasma BNP level after RMA.
Conclusions: There may be a signiﬁcant association between LV reverse remodeling and plasma BNP
change after RMA. Furthermore, LV end-systolic myocardial stress may be the key mechanical stimulus
inﬂuencing plasma BNP after surgical correction for functional MR. Whether these favorable BNP
responses and reverse remodeling can predict improved survival requires further study.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Heart failure is a major public health problem. Functional mitral
regurgitation (MR) is a common complication of both ischemic and
non-ischemic advanced cardiomyopathy, and the presence of reserved.
S. Kainuma et al. / Journal of Cardiology 66 (2015) 279–285280functional MR in the setting of severe systolic left ventricular (LV)
dysfunction (advanced cardiomyopathy) is strongly associated
with poor outcome [1].
Restrictive mitral annuloplasty (RMA) using an undersized
prosthetic ring is a preferred surgical option to treat moderate to
severe functional MR. Previous observational studies demonstrat-
ed that surgical mitral annuloplasty [2–5] can effectively eliminate
functional MR and promote LV reverse remodeling, thus yielding
other hemodynamic changes and improvements in exercise
capacity and New York Heart Association (NYHA) functional class.
Other reports have also noted that plasma B-type natriuretic
peptide (BNP) concentration, a strong predictor of prognosis in
patients with heart failure, was signiﬁcantly reduced after RMA
[2,6]. Although these beneﬁcial changes suggest the possible
effectiveness of surgical treatment in modifying natural history of
the disease, the impact of mitral valve annuloplasty on survival
remains under discussion [2,7–9], highlighting the need for a
comprehensive understanding of the neurohormonal response
mechanism before and after surgical intervention for functional
MR.
Systolic wall stress is a reasonable surrogate for LV afterload
and the major determinant of LV systolic function [10], although it
is considerably difﬁcult to assess regional and global myocardial
stress in left ventricles with different shapes. Multi-detector
computed tomography (MDCT) is an emerging technique that
enables more accurate and reproducible contour deﬁnition than
echocardiography. We recently developed MDCT-based analysis
software for computing global and regional circumferential
myocardial stress [3,11]. In the present study, we hypothesized
that change in systolic myocardial stress, an index of afterload, is a
key factor that mainly contributes to LV reverse remodeling and
neurohormonal response after surgical correction of MR. To test
our hypothesis, we aimed to determine the association between
response of plasma BNP and changes in LV function parameters (LV
volume, performance and wall stress) in patients undergoing RMA
for functional MR, utilizing the serial measurements with cardiac
MDCT and our software.
Materials and methods
Study patients
The study population consisted of 24 patients who underwent
64-row MDCT and plasma BNP measurements before and after
RMA between 2007 and 2010 (Table 1). All had a diagnosis of
advanced cardiomyopathy [LV ejection fraction (EF) <40%] and
congestive heart failure symptoms despite receiving maximalTable 1
Patient characteristics.
Variables Entire cases (n = 24)
Demographics
Age (years) 64  10
Males 22 (91.7%)
Body surface area (m2) 1.72  0.18







ACE inhibitors 6 (25.0%)
Angiotensin II receptor blockers 12 (50.0%)
Diuretics 19 (79.2%)
NYHA, New York Heart Association; ACE, angiotensin-converting enzyme.medical treatment. Each had clinically important functional MR
(moderate to severe MR or regurgitant volume 30 ml/beat)
secondary to LV remodeling and systolic restrictive motion of
mitral leaﬂets in echocardiography ﬁndings. Patients with recent
myocardial infarction (<3 months), organic MR, or rheumatic
mitral disease, and those who underwent concomitant surgical
ventricular reconstruction were excluded from analysis. The study
protocol was approved by an institutional review board and all
patients provided informed consent.
Surgical procedures
All operations were performed through a median sternotomy
under a mild hypothermic cardiopulmonary bypass, with ante-
grade and retrograde intermittent cold blood cardioplegia. Ring
size was determined after careful intraoperative measurements of
anterior leaﬂet height and intertrigonal distance and then down-
sizing by 2 to 3 sizes. No other adjunct procedures were performed
on the valve itself. Consequently, the annuloplasty ring implanted
was 24 mm in 14 (58%), 26 mm in 7 (29%), and 28 mm in 3 (13%),
respectively. Simultaneous procedures included coronary artery
bypass grafting (CABG) in 15 (63%) and tricuspid annuloplasty in
20 (83%).
Cine-MDCT angiography
The protocol of cine-MDCT angiography was described in detail
previously [3,11]. LV end-diastolic volume (LVEDV) and end-
systolic volume (LVESV) were obtained from the largest and
smallest LV chamber MDCT images, respectively. LVEF was
calculated as [(LVEDV  LVESV)/LVEDV]  100. LV volumes were
indexed for body surface area (LVEDVI and LVESVI, respectively).
All image processing was veriﬁed by well-experienced radiologists
(S.H. and K.K.).
Left ventricular end-systolic pressure estimation
Blood pressure was obtained non-invasively by a digital
sphygmomanometer (cuff) before each MDCT examination. In
this study, LV end-systolic pressure was calculated with the
following equation: P = 0.98  (systolic blood pressur-
e + 2  diastolic blood pressure)/3 + 11 mmHg [12].
Regional and global myocardial wall stress
Regional and global myocardial stresses were determined using
a personal computer with dedicated analysis software (Osaka
University-OSCAR STRESS tool, Osaka, Japan; YD, Ltd, Ikoma, Nara,
Japan) [3,11]. Regional end-systolic stress (ESS) was calculated on
the basis of Janz’s method [13] as follows: Regional
ESS = 1.332  P  DAC/DAW, where P is LV end-systolic pressure,
DAC and DAW are local cross-sectional area of the LV cavity and the
cross-sectional area of the LV wall at end-systole, respectively. In
the present study, to simplify the display and analysis of regional
ESS, 3 LV levels (base, mid, and apex) were determined with
reference to long axis and 3 perpendicular short axes at equal
intervals. The global ESS was deﬁned as the average values of
regional ESS for each element, e.g. basal, mid, or apex-LV short-axis
slice, calculated for each patient. All measurements were repeated
2 times, and the average value was used as a ﬁnal one.
Measurements of plasma B-type natriuretic peptide
Blood samples were drawn from the antecubital vein earlier
in the day of MDCT assessment. Plasma BNP levels were
measured directly with validated and commercially available
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Tokyo, Japan).
Follow-up examinations
Every 6 months to 1 year, each patient was assessed in the
department as well as by their primary cardiologist. Functional
status was assessed according to NYHA criteria for symptoms of
heart failure and plasma BNP level. Clinical follow-up examina-
tions were completed for all patients (100%) with a mean duration
of 33  11 months.
Statistical analysis
Categorical data are shown as frequencies and proportions, and
were compared using chi-square analysis or Fisher’s exact test, as
appropriate. Continuous data are presented as the mean  stan-
standard deviation or median with interquartile ranges (IQR), and
were compared using Student’s t test or Mann–Whitney U test, as
appropriate. Preoperative and postoperative variables were assessed
by Wilcoxon signed rank test or repeated-measures analysis of
variance (ANOVA), with group, time, and group–time interaction
effects. Non-normally distributed variables tested in the repeated
ANOVA were natural log-transformed to satisfy normality of the used
models, as appropriate. The plasma BNP level was natural log-
transformed (Ln) to satisfy the normality of the used models, and
correlations between Ln BNP and hemodynamic variables were tested
with Pearson’s correlation coefﬁcient (r).
Multiple linear regression analysis was used to deﬁne the
independent determinants for change in Ln BNP. Factors obtaining
a p-value less than 0.1 in the univariate analysis were then entered
appropriately into multivariate analysis. The results are summa-
rized as correlation coefﬁcients (r) and standardized partial
regression coefﬁcients (SPRCs). All p-values are 2-sided and values
of p < 0.05 were considered to indicate statistical signiﬁcance.
Statistical analyses were performed using JMP 7.0 (SAS Institute,
Cary, NC, USA), SAS (version 9.2, SAS Institute), and SPSS (version
17.0, SPSS Inc.) statistical software.
Results
Symptoms and plasma BNP before and late after RMA
MR degree was less than grade 2+ in all patients immediately
after surgery and signiﬁcantly decreased from 3.5  0.6 at baselineFig. 1. NYHA functional class and plasma BNP levels at baseline and latest follow-up ex
natriuretic peptide.to 0.5  0.8 (p < 0.0001) at 1 month after surgery. The proportion of
patients with NYHA class I (no symptoms) or II heart failure increased,
while that of those with class III or IV heart failure decreased from
baseline to the last follow-up visit (Fig. 1). The symptoms improved
by an average NYHA class score of 1.1. The median value for plasma
BNP decreased from 597 pg/ml (IQR, 360–935 pg/ml) at baseline to
207 pg/ml (IQR, 124–271 pg/ml) at 1.4 months (IQR, 1.0–2.4 months)
after surgery (mean reduction, 48%). The proportion of patients with
plasma BNP <100 pg/ml or 100–299 pg/ml increased, while that of
those with BNP at 300–500 pg/ml or >500 pg/ml decreased from
baseline to the last follow-up visit (Fig. 1).
Change in Ln plasma BNP was positively correlated with that in
NYHA functional class (r = 0.50, p = 0.011).
Changes in LV ejection performance and wall stress before and after
RMA
All patients underwent 64-row MDCT (SOMATOM Deﬁnition
Dual Source CT, Siemens, Erlangen, Germany) within 1 month
before (at baseline) and 1.4 months (IQR, 1.0–2.4 months) after
RMA. Heart rate and blood pressure at the time of image
acquisition were not signiﬁcantly changed in postoperative
examinations (Table 2). LVEDVI and LVESVI were decreased and
LVEF increased signiﬁcantly after surgery (Fig. 2). Regional ESS
was signiﬁcantly reduced at the basal, mid, and apex-ventricular
levels. Consequently, global ESS was signiﬁcantly decreased
(Fig. 2).
There were signiﬁcant correlations between DLVEDVI and
DLVESVI (r = 0.90, p < 0.0001), DLVESVI and Dglobal ESS (r = 0.54,
p = 0.006), and Dglobal ESS and DLVEF (r = 0.60, p = 0.002),
indicating a strong association between decrease in afterload and
improvement in ejection performance after RMA.
Relationship between LV reverse remodeling and BNP response after
RMA
There was a substantial correlation between Ln BNP value and
those for LVEDVI (r = 0.25, p = 0.083), LVESVI (r = 0.32, p = 0.028),
LVEF (r = 0.39, p = 0.006), and LV global ESS (r = 0.50, p = 0.0002)
(Fig. 3). The relationship to global ESS showed the highest
correlation coefﬁcient.
DLn BNP was positively correlated with Dheart rate, DLVEDVI,
DLVESVI, and Dglobal ESS, and negatively with DLVEF (Table 3).
Results of multivariate regression analysis showed that Dglobal
ESS had the most important contribution to DLn BNP, whichamination (median, 48 months). NYHA, New York Heart Association; BNP, B-type
Table 2
Pre- and postoperative hemodynamics, LV function, and wall stress.
Variables Pre-op (n = 24) Post-op (n = 24) Percent change (%) p-value
Plasma BNP (pg/ml), median (IQR) 597 (360–935) 207 (124–271) 48  36 <0.0001
Hemodynamics
Heart rate (beats/min) 77  17 76  13 0.778
Systolic blood pressure (mmHg) 118  25 115  21 0.399
Diastolic blood pressure (mmHg) 69  16 66  12 0.247
Mean arterial pressure (mmHg) 86  18 82  15 0.243
End-systolic pressure (mmHg) 96  18 89  15 0.063
LV volume and function
LVEDVI (ml/m2) 134  26 117  34 13  17 0.003
LVESVI (ml/m2) 100  27 78  33 22  26 0.0003
LVEF (%) 26  7 36  13 9  12a 0.001
Global ESS (kdyne/cm2) 246  34 194  34 20  15 <0.0001
Basal average ESS (kdyne/cm2) 265  42 202  28 22  15 <0.0001
Mid average ESS (kdyne/cm2) 266  42 223  45 15  16 0.0002
Apex average ESS (kdyne/cm2) 196  59 157  40 21  20 0.002
Pre-op, preoperative; Post-op, postoperative; BNP, B-type natriuretic peptide; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic
volume index; LVEF, left ventricular ejection fraction; ESS, end-systolic wall stress.
a Absolute change from baseline to 1.4 months after surgery.
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and reduction in plasma BNP level after RMA.
Impact of RMA with or without CABG on postoperative LV reverse
remodeling and function
Preoperative clinical proﬁle of patients who received RMA alone
and those who received RMA plus CABG is summarized in the
supplemental data 1. There were no signiﬁcant differences in the
demographics between the groups, except for a higher prevalence
of ischemic etiology of heart failure in patients who received RMA
plus CABG, as compared with those who received RMA alone.
From baseline to 1 month after surgery, RMA alone group
decreased LVEDVI by 12% and LVESVI by 21%, yielding improved
LVEF (absolute change 9.8  14.5%). Similarly, RMA plus CABG
decreased LVEDVI by 13% and LVESVI by 23%, yielding improved LVEF
(absolute change 8.7  10.3%). Importantly, there were no differences
between the groups with regard to the magnitude of change in LVFig. 2. Absolute and percent changes in the LVEDVI, LVESVI, and EF from baseline
(before surgery) to 1.4 months after surgery. LVEDVI, left ventricular end-diastolic
volume index; LVESVI, left ventricular end-systolic volume index; EF, ejection
fraction.volumes and improvement in LVEF, as well as decrease in LV global
ESS (interaction effect p > 0.05 for all) (supplemental data 2).
Discussion
This is the ﬁrst study to examine the association among LV
reverse remodeling, myocardial wall stress, and changes in plasma
BNP concentration after surgical correction of functional MR in
patients with cardiomyopathy. We used cine-MDCT images, an
emerging technique that enables more accurate and reproducible
contour deﬁnition than echocardiography, along with our in-house
software to measure LV volumes, function, and regional and global
myocardial wall stress. The following results were obtained: (1)
RMA effectively eliminated functional MR and improved symp-
toms, (2) RMA abolished LV volume overload and partially
reversed LV remodeling, and reduced LV end-systolic wall stress
and plasma BNP concentration, (3) the reduction in myocardial
wall stress was signiﬁcantly associated with improvement in LVEF,
and, most importantly, (4) among the LV function parameters
measured with cine-MDCT images, change in systolic wall stress
was signiﬁcantly correlated with decrease in plasma BNP at
1.4 months after RMA. Together, these ﬁndings indicate that
decreased systolic wall stress (LV afterload reduction), derived
from LV volume unloading conferred by RMA with optimal medical
treatment, is the major factor contributing to both improved LV
ejection performance and reduced plasma BNP concentration.
It was once believed that the presence of chronic MR creates a
systolic unloading effect by providing a low resistance ejection into
the left atrium [14]. This traditional hypothesis held that the mitral
valve functions as a ‘‘pop-off valve’’ for the failing ventricle and
surgical correction might have prohibitive risks in patients with
severely remodeled LV because of postoperative afterload (systolic
myocardial wall stress) excess and subsequent decline in LV
ejection performance [3,11]. However, several recent studies
showed that RMA procedure could induce reverse LV remodeling
(decrease in LV volumes and increase in ejection fraction) after
correction of MR in failing ventricle [15–18]. This controversial fact
was partially settled by the previous publication from Takeda and
colleagues which conﬁrmed a strong association between the
improvement in LV ejection fraction and the reduction in LV end-
systolic wall stress in patients with advanced cardiomyopathy who
received RMA procedure. This indicates that the mechanism of
reverse LV remodeling process is related to the afterload reduction
derived from ventricular volume unloading by eliminating MR
[3]. Those ﬁndings lead us to hypothesize that reduction in systolic
Fig. 3. Associations between Ln BNP and LVEDVI, LVESVI, LVEF, and global ESS. The open and ﬁlled circles indicate values without hemodialysis at baseline and 1.4 months
after surgery, respectively. Open and ﬁlled triangles indicate values in the cases with hemodialysis. Ln, natural log-transformed; BNP, B-type natriuretic peptide; LVEDVI, left
ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; ESS, end-systolic wall stress.
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reverse remodeling and plasma BNP changes after surgical
correction of MR, although the relationship between LV afterload
reduction and relief of neurohormonal activation was not fully
investigated in their studies.
BNP is a hormone of cardiac origin that is released from the
ventricular myocardium in response to cardiac overload [19]. In
experimental studies, cardiac myocyte stretch is the key stimulus
for BNP production and release [20], whereas that for BNP releaseTable 3




DHeart rate (beats/min) 0.421 
DSystolic blood pressure (mmHg) 0.130 
DDiastolic blood pressure (mmHg) 0.046 
DMean arterial pressure (mmHg) 0.026 
DEnd-systolic pressure (mmHg) 0.002 
LV volume and function
DLVEDVI (ml/m2)a 0.471 
DLVESVI (ml/m2) 0.560 
DLVEF (%) 0.599 
DGlobal ESS (kdyne/cm2) 0.737 
D indicates postoperative value minus preoperative value. SPRC, standardized partial r
left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; ES
a DLVEDVI was not entered into the multivariate analysis because of a strong correlin the clinical setting of systolic heart failure remains controversial.
Some human studies have found that LV end-diastolic pressure or
stress is the most important hemodynamic parameter regulating
the level of circulating BNP [21], while others have noted that
LVESVI or LV end-systolic wall stress is the key parameter for
cardiac BNP release, indicating that LV geometry and systolic
stress, rather than diastolic ﬁlling pressure or diastolic stress, are
the most important mechanical determinants of cardiac BNP












egression coefﬁcient; LVEDVI, left ventricular end-diastolic volume index; LVESVI,
S, end-systolic wall stress.
ation between DLVEDVI and DLVESVI (r = 0.901).
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RMA may support the conclusions of the latter studies. Further-
more, this is a novel ﬁnding indicating a possible hemodynamic
factor that contributes to changes in BNP after RMA in patients
with severe systolic LV dysfunction. However, the hemodynamic
determinants of BNP production and release, especially the relative
contributions of systolic and diastolic wall stress, remain to be
elucidated.
The impact of RMA on late survival in patients with signiﬁcant
functional MR remains controversial. In a previous study, there
was no clearly demonstrable mortality beneﬁt conferred by RMA
as compared with medical therapy [7]. Some studies reported a
lack of long-term functional improvements and survival beneﬁt
over and above that of medical therapy, including b-blockers or
cardiac resynchronization therapy [24,25]. In addition, many
other studies have failed to demonstrate long-term survival
beneﬁts for patients with ischemic functional MR who under-
went RMA plus CABG as compared with patients treated with
CABG alone [2,5,8]. On the other hand, Deja et al. analyzed the
impact of RMA on survival in the recently reported Surgical
Treatment for Ischemic Heart Failure (STICH) trial and suggested
that adding MV annuloplasty to CABG may improve survival as
compared with CABG or medical therapy alone [9]. It is well
established that systolic wall stress is a strong prognostic
indicator in patients with systolic LV failure. Plasma BNP
concentration is also an important prognostic indicator in heart
failure [26], while changes in BNP have been shown to be
associated with corresponding improvement in survival [27]. Pri-
or to surgical referral, most of our patients had been treated with
optimal medical therapy. Therefore, the present results indicate
that performance of RMA in patients with advanced cardiomy-
opathy and moderate to severe MR may consistently reverse LV
remodeling, reduce systolic wall stress and plasma BNP and,
consequently, yield a corresponding improvement in long-term
survival.
The effects of RMA without CABG on postoperative LV reverse
remodeling and function are uncertain. Many surgeons and
cardiologists are not conﬁdent regarding beneﬁcial effects on LV
function gained from the RMA procedure alone. In a prior study,
Takeda et al. [3] used cine-MDCT to investigate the effects of RMA
on LV volumes and function in 24 patients with dilated
cardiomyopathy (13 non-ischemic, 11 ischemic) and functional
MR, and found a 13% reduction in LVEDVI, 21% reduction in LVESVI,
and improvement in LVEF from 27% at baseline to 33% at
2.3 months after surgery. Their overall results are consistent with
those of the present study. Additionally, we found that the changes
in LV volume, function, systolic wall stress, and plasma BNP level
from baseline to 1.4 months after surgery were similar between
patients with and without concomitant CABG. Together, these
results indicate that the beneﬁcial changes during the acute phase
of surgical intervention are at least partly related to LV volume
unloading and afterload reduction conferred by RMA.
Relation to previous studies
The reduction in LVESVI of 22% observed in our MDCT study is
consistent with that reported in a recent study [2], in which LVESVI
was measured using cardiac magnetic resonance (CMR), the gold
standard for LV volume measurement. In that study, LVESVI in
patients with ischemic cardiomyopathy who underwent mitral
valve repair during CABG was reduced by 28% after 1 year. In
contrast, Westenberg et al. conducted a CMR study [28] and
reported that LVESV was not signiﬁcantly changed at 2 months or
1 year after RMA in patients with early-stage non-ischemic
cardiomyopathy. On the other hand, in their initial echocardio-
graphic study, Bolling et al. [4] observed a reduction in LVESV of15% after 4–6 months in patients with end-stage dilated
cardiomyopathy. These contrasting results may be attributable
to differences regarding disease etiologies, degrees of LV remodel-
ing progression, MR quantiﬁcation, time of follow-up examina-
tions, suboptimal annuloplasty techniques, and incomplete
coronary artery revascularization. Interestingly, the cases pre-
sented by Westenberg et al. showed a signiﬁcantly smaller LVESV
value at baseline, indicating early stage cardiomyopathy with less
LV remodeling, as compared with other studies.
The results of plasma BNP levels after RMA in this study are
consistent with an observational study [6] and randomized trial
[2]. Paparella et al. [6] observed that mean BNP decreased from
471 pmol/L to 56 pmol/L at 6 months after surgery in patients
who underwent CABG combined with RMA. They speculated
that a greater postoperative decrease in BNP was associated
with more extensive LV reverse remodeling. Chan et al. also
found that BNP decreased from 748 pg/ml to 191 pg/ml (75%
reduction) in their CABG plus RMA group as compared with a
lower amount of decrease from 681 pg/ml to 287 pg/ml (58%
reduction) in patients who underwent CABG alone (p = 0.003).
They speculated that a persistent elevation in BNP level
suggested persistent LV dysfunction and patients with BNP
>100 pg/ml remain at high risk for cardiovascular mortality and
morbidity, which was consistent with our results. Additional
randomized studies with higher numbers of patients and longer
follow-up periods are necessary to better conﬁrm whether these
favorable BNP responses and reverse remodeling can predict
improved survival.
Limitations
This study was retrospective in nature and investigated a small
number of subjects; thus, our results should be interpreted
cautiously until veriﬁed in an independent, prospective study.
Inclusion of patients with different etiologies for heart failure and
those who had undergone concomitant surgical intervention
might have inﬂuenced the results. In addition, the perioperative
multimodal treatments might have affected the change in the
plasma BNP. However, the preoperative medical therapies were
continued without any modiﬁcation after surgical intervention. In
particular, the use and dosage of angiotensin-converting enzyme
inhibitors and angiotensin-II receptor blockers were not changed;
thus, their inﬂuence on the change in the plasma BNP might be
considered to be negligible.
Lack of data regarding end-diastolic wall stress prevented us
from determining relative contributions of systolic and diastolic
wall stress on change in plasma BNP after RMA. Finally, we
measured changes in the LV volumes, wall stress, and plasma BNP
during the short-term period after surgery. The data with
additional follow-up computed tomography scans would help us
to discuss the long-term efﬁcacy of RMA for functional MR, which
remains to be determined. Despite these limitations, our ﬁndings
may help elucidate therapeutic response mechanism and provide
an impetus for the treatment strategy aimed at afterload reduction
in patients with advanced cardiomyopathy.
Conclusion
There may be a signiﬁcant association between LV reverse
remodeling and plasma BNP change after RMA. Furthermore, LV
end-systolic myocardial stress may be the key mechanical
stimulus inﬂuencing plasma BNP after surgical correction for
functional MR. Whether these favorable BNP responses and
reverse remodeling can predict improved survival requires further
study.
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